lifestyle.mmminimal.com

Author: Moderna, Inc.

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

January 22, 2026
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

January 5, 2026
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Vaccine Candidate

December 20, 2025
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 19, 2025
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s mNEXSPIKE (COVID-19 Vaccine, mRNA)

December 15, 2025